Fidaxomicin als Alternative zu Vancomycin bei Clostridium-difficile-Infektion

Literatur

• 1 Bauer M P, Notermans D W, van Benthem B H et al. Clostridium difficile infection in Europe: a hospital-based survey.  Lancet. 2011;  377 63-73
• 2 Vonberg R P, Reichardt C, Behnke M et al. Costs of nosocomial Clostridium difficile-associated diarrhoea.  J Hosp Infect. 2008;  70 5-20
• 3 Louie T J, Miller M A, Mullane K M et al. Fidaxomicin versus vancomycin for Clostridium difficile infection.  N Engl J Med.. 2011;  364 422-431
• 4 Tannock G W, Munro K, Taylor C et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.  Microbiolology. 2010;  156 3354-3359
• 5 Lowy I, Molrine D C, Leav B A et al. Treatment with monoclonal antibodies against Clostridium difficile toxins.  N Engl J Med.. 2010;  362 197-205